Ultragenyx Settles Dojolvi Patent Litigation With Navinta
Bitget2026/10/19 13:08- Ultragenyx Pharmaceutical and Baylor Research Institute settled DOJOLVI patent litigation with Navinta on October 19, 2026.
- Navinta will receive a non-exclusive, royalty-free license to market generic DOJOLVI beginning January 1, 2033, subject to customary conditions and exceptions.
- The launch date would move to July 1, 2033, if DOJOLVI receives pediatric exclusivity.
- The litigation stemmed from Navinta's application for FDA approval of a generic version of DOJOLVI oral liquid.
- Similar DOJOLVI patent litigation against other generic applicants remains pending in the U.S. District Court for the District of New Jersey.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The New York Stock Exchange extends trading hours for some options, with Nvidia, Alibaba, and others among the first batch selected
NYSE American, an options exchange under the New York Stock Exchange, officially launched extended trading hours on Monday: the pre-market session runs from 7:30 a.m. to 9:25 a.m. ET, and the post-market session is from 4:00 p.m. to 4:15 p.m. The initial batch includes ETF options tracking assets such as the S&P 500, Russell 2000, and gold, as well as related options for companies like Apple, Microsoft, Nvidia, Alibaba, TSMC, Alphabet, Amazon, and Oracle. NYSE also plans to extend similar arrangements to the stock market in December.

Playstudios Regains Compliance With Nasdaq Minimum Bid Price Requirement
42% of Americans Want Crypto-Friendly Banks, but Financial Advice Falls Short
